CORT - Corcept Therapeutics

-

$undefined

N/A

(N/A)

Corcept Therapeutics NasdaqCM:CORT Corcept Therapeutics Incorporated engages in discovery and development of medication for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. It offers Korlym tablets medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous cushing's syndrome; and who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery. The company is also developing relacorilant, which is in phase III clinical trial for the treatment of hypercortisolism; relacorilant combined with nab-paclitaxel which is in phase III clinical trial to treat platinum-resistant ovarian tumors; treatment for adrenal cancer and cortisol excess which is in phase 1b clinical trial; and for treatment for prostate cancer which is in phase II clinical trial. In addition, it develops dazucorilant, which is in phase II clinical trial for the treatment of amyotrophic lateral sclerosis; and miricorilant, which is in phase IIb trial for the treatment of metabolic dysfunction-associated steatohepatitis. The company was incorporated in 1998 and is headquartered in Redwood City, California.

Location: 101 Redwood Shores Parkway, Redwood City, CA, 94065, United States | Website: https://www.corcept.com | Industry: Biotechnology | Sector: Healthcare


Market Cap

NaN

52 Wk Range

$ - $

Previous Close

$N/A

Open

$N/A

Day Range

N/A - N/A

Volume

N/A

Avg Volume

N/A

Enterprise Value

7.917B

Cash

322.8M

Avg Qtr Burn

N/A

Short % of Float

14.24%

Insider Ownership

11.48%

Institutional Own.

79.82%

Qtr Updated

03/31/25


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
Korlym® (Relacorilant) Details
Hypercortisolism, Cushing’s syndrome

Phase 4

Data readout

PDUFA

Approval decision

Relacorilant + Nab-paclitaxel Details
Platinum-Resistant Ovarian Cancer​

NDA

Submission

Korlym® (Relacorilant) Details
Hypercortisolism, Cushing’s syndrome

NDA

Submission

Miricorilant Details
Non-alcoholic steatohepatitis

Phase 2b

Data readout

Relacorilant (GR antagonist) + Enzalutamide Details
Cancer, Castration-resistant prostate cancer, Solid tumor/s, Prostate cancer

Phase 2

Data readout

Phase 2

Data readout

Dazucorilant Details
Amyotrophic lateral sclerosis

Susp. Mover™

Phase 2

Data readout

Miricorilant Details
Obesity, Antipsychotic-Induced Weight Gain

Phase 2

Update

Phase 1b

Update

Failed

Discontinued